JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

42.24 2.08

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

40.57

Максимум

42.7

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+30.76% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-27M 3.2B
Предишно отваряне	40.16
Предишно затваряне	42.24

Настроения в новините

By Acuity

50%

139 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.02.2026 г., 23:57 ч. UTC

Пазарно говорене

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8.02.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8.02.2026 г., 23:34 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.02.2026 г., 23:34 ч. UTC

Пазарно говорене

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8.02.2026 г., 23:26 ч. UTC

Пазарно говорене

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8.02.2026 г., 22:55 ч. UTC

Печалби

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8.02.2026 г., 21:43 ч. UTC

Пазарно говорене

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8.02.2026 г., 21:16 ч. UTC

Пазарно говорене

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8.02.2026 г., 21:15 ч. UTC

Пазарно говорене

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7.02.2026 г., 09:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

7.02.2026 г., 09:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.02.2026 г., 05:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

7.02.2026 г., 02:46 ч. UTC

Придобивния, сливания и поглъщания

Big Money, High Anxiety -- Barrons.com

6.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

6.02.2026 г., 21:40 ч. UTC

Придобивния, сливания и поглъщания

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6.02.2026 г., 21:22 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Accelerating in January -- Market Talk

6.02.2026 г., 21:17 ч. UTC

Печалби

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6.02.2026 г., 21:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.02.2026 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6.02.2026 г., 21:13 ч. UTC

Печалби

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6.02.2026 г., 21:13 ч. UTC

Печалби

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6.02.2026 г., 21:04 ч. UTC

Пазарно говорене

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6.02.2026 г., 20:34 ч. UTC

Печалби

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

30.76% нагоре

12-месечна прогноза

Среден 54.11 USD 30.76%

Висок 62 USD

Нисък 44 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

139 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.